ficerafusp alfa
ficerafusp alfa: developed by 1 company · 4 clinical trials tracked.
ficerafusp alfa evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could ficerafusp alfa → BCAX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Bicara Therapeutics Inc. (BCAX) | Phase 3 |
| Bicara Therapeutics Inc. (BCAX) Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2/Phase 3 |
Clinical Trials (4)
Phase I/II Trial of Neoadjuvant Combination of Ficerafusp Alfa, Pembrolizumab, and SBRT for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Primary endpoint: Phase I only: Maximum tolerated dose (MTD) of SBRT in combination with pembrolizumab plus ficerafusp alfa
A Phase II Study of Ficerafusp Alfa (BCA 101) in Combination With Nivolumab in Platinum Refractory Head and Neck Squamous Cell Carcinoma Patients Who Progressed Within 6 Months After Multimodal Treatment for Locally Advanced Disease ( BICARA)
Primary endpoint: Objective response rate (ORR)
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable Squamous Cell Carcinoma of the Head and Neck: a Phase 2 Trial
Primary endpoint: Pathologic Treatment Response-2 (pTR-2) Rate
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Primary endpoint: Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Frequently asked questions
Who is developing ficerafusp alfa?
ficerafusp alfa is being developed by Bicara Therapeutics Inc..
How many clinical trials involve ficerafusp alfa?
BioSniper tracks 4 clinical trials involving ficerafusp alfa.